(Q44563629)

4 December 2017

Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases (English)

1 reference

4 December 2017

Yihan Wang

1

1 reference

4 December 2017

Chester A Metcalf

2

1 reference

4 December 2017

William C Shakespeare

3

1 reference

4 December 2017

Raji Sundaramoorthi

4

1 reference

4 December 2017

Terence P Keenan

5

1 reference

4 December 2017

Regine S Bohacek

6

1 reference

4 December 2017

Marie Rose van Schravendijk

7

1 reference

4 December 2017

Shiela M Violette

8

1 reference

4 December 2017

Surinder S Narula

9

1 reference

4 December 2017

David C Dalgarno

10

1 reference

4 December 2017

Chad Haraldson

11

1 reference

4 December 2017

Jeffrey Keats

12

1 reference

4 December 2017

Shuenn Liou

13

1 reference

4 December 2017

Ukti Mani

14

1 reference

4 December 2017

Selvi Pradeepan

15

1 reference

4 December 2017

Mary Ram

16

1 reference

4 December 2017

Susan Adams

17

1 reference

4 December 2017

Manfred Weigele

18

1 reference

4 December 2017

Tomi K Sawyer

19

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Bioorganic & Medicinal Chemistry Letters

4 December 2017

1 reference

4 December 2017

13

1 reference

4 December 2017

18

1 reference

4 December 2017

3067-3070

1 reference

Cellular functions regulated by Src family kinases

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

v-Src's hold over actin and cell adhesions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

c-Src, receptor tyrosine kinases, and human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Src kinase contributes to the metastatic spread of carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Substrate recognition by osteoclast precursors induces C-src/microtubule association.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Decreased c-Src expression enhances osteoblast differentiation and bone formation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Src inhibitors: genomics to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Targeting protein kinases for bone disease: discovery and development of Src inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Bisphosphonates as a foundation of drug delivery to bone

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Three-dimensional structure of the tyrosine kinase c-Src

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900648-6

7 January 2021

10.1016/S0960-894X(03)00648-6

Identifiers

DOI

1 reference

4 December 2017

1 reference